Sfoglia per AUTORE
RE F
Collezione AO Cuneo

  

Items : 6

Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. in Hematological oncology / Hematol Oncol. 2023 Oct;41(4):655-662. doi: 10.1002/hon.3184. Epub 2023 May 28.

2023
AO Cuneo
ASL Biella

Gini G; Federico M; Luminari S; Marcheselli L; Catellani H; Skrypets T; Stefani PM; Pastore D; Pennese E; Liberati AM; Ballerini F; Vitolo U; Usai SV; Capponi M; Galimberti S; Perrone T; Re F; Mannina D; Musto P; Conconi A; Bari A; Massaia M; Ghiggi C; Pulsoni A; Musuraca G; Califano C; Merli M; Manni M; Nizzoli ME; et alii...

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. in Blood / Blood. 2022 Sep 22;140(12):1378-1389. doi: 10.1182/blood.2021014270.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Alessandria

Liberati AM; Ladetto M; Cortelazzo S; Ghiggi C; Cascavilla N; Musuraca G; Hohaus S; Re F; Petrini M; Pavone V; Casaroli I; Castellino C; Zanni M; Benedetti F; Stefani PM; De Luca G; Evangelista A; Genuardi E; Drandi D; Zaccaria GM; Alessandria B; Ghislieri M; Mantoan B; Ferrante M; Ferrero S; Grimaldi D;

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.

2021
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Foà R; Chiarenza A; Penna G; Gottardi D; Derenzini E; Levato L; Orsucci L; Gattei V; Gentile M; Sanna A; Gozzetti A; Olivieri J; Murru R; Baratè C; Leone M; Stefoni V; Malerba L; Ibatici A; Tisi MC; Marasca R; Chiurazzi F; Varettoni M; Farina L; Del Poeta G; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; et alii...

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). in Haematologica / Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.

2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria

Foà R; Guarini AR; Raponi S; De Propris MS; Della Starza I; Del Giudice I; Albano F; Cuneo A; Neri A; Piciocchi A; Vignetti M; Nanni M; Musolino C; Battistini R; Del Poeta G; Pietrasanta D; Gozzetti A; Liberati AM; Reda G; Tedeschi A; Re F; Soddu S; Mauro FR; Angelucci E; Zaja F; Coscia M; Ilariucci F; Molica S;

First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study in Journal of Clinical Oncology

2019
AO Cuneo

Loges S; Heuser M; Chromik J; Vigil CE; Paschka P; Re F; Di Renzo N; Lemoli R; Mattei D; Batalla IB; Hellesøy M; Micklem D; Holt RJ; Lorens K; Lorens JB; Shoaib M; Aly H; Fiedler WM; Cortes JE; Gjertsen BT;